CurrentCignaPolicy N/A

Parkinson's Disease - Tolcapone Prior Authorization Policy

Defines Cigna's prior authorization requirements and medical necessity criteria for tolcapone (Tasmar) prescription benefit coverage for patients with Parkinson's disease, including prescriber qualifications and trial of alternative COMT inhibitors.

Policy Summary

PayerCigna

PolicyParkinson's Disease - Tolcapone Prior Authorization Policy

Policy CodePolicy N/A

Change TypeRevised clinical requirement

Effective DateN/A

Next Review DateMar 25, 2026

Key ActionObtain prior authorization and document patient is on carbidopa/levodopa with prior trial of entacapone or Ongentys (opicapone) and neurologist prescribing/consultation.

SourceLink

POLICY UPDATE CHANGES

Requirement that the patient has tried an entacapone product was changed to the patient has tried an entacapone product or Ongentys (opicapone capsules).

1 yearstandard approval duration for tolcapone when criteria met

Boxed Warningboxed warning - liver failure risk

requires neurologistrequires neurologist

trial requiredtrial required

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: COVERAGE CRITERIA — Covered when ALL of the following are met for FDA-approved indication (Parkinson's Disease):

Covered when ALL of the following are met for FDA-approved indication (Parkinson's Disease):

FDA-Approved Indication Criteria

A: Patient is currently receiving carbidopa/levodopa therapy
B
- ONE of: According to the prescriber, patient had significant intolerance to an entacapone product or opicapone (Ongentys)
- ONE of: According to the prescriber, patient had inadequate efficacy with an entacapone product or opicapone (Ongentys)
C: The medication is prescribed by or in consultation with a neurologist

Tolcapone (Tasmar®) is considered not medically necessary for any use(s) other than those specified in this policy. Requests for tolcapone for indications outside the defined coverage criteria will not be approved.

Use of tolcapone for indications other than Parkinson's disease is considered not medically necessary and will be denied. The policy’s conditions not covered specify that tolcapone products are not medically necessary for any other use(s) and that criteria will be updated as new data become available.

Provider Actions and Prior Authorization

Prior Authorization

Prior authorization required; 1-year approval when criteria met

Prior authorization is required for tolcapone. Approvals are for 1 year when the patient is currently receiving carbidopa/levodopa, has tried an entacapone product or Ongentys (opicapone) with documented intolerance or inadequate efficacy, and the medication is prescribed by or in consultation with a neurologist.

Step Therapy

Step therapy: trial of entacapone or opicapone required

Patient must have trialed an entacapone product or Ongentys (opicapone capsules) before tolcapone is approved, unless the prescriber documents significant intolerance or inadequate efficacy.

Documentation Required

Required documentation: levodopa/carbidopa use, prior trial and outcome, neurologist involvement

Document that the patient is currently receiving carbidopa/levodopa, the prior trial of an entacapone product or Ongentys (opicapone) and the outcome (significant intolerance or inadequate efficacy per prescriber), and that tolcapone is prescribed by or in consultation with a neurologist.

Denial Risk

Grounds for denial: non‑PD use or unmet prior‑auth criteria

Request may be denied if tolcapone is requested for any indication other than Parkinson's disease or if required prior authorization criteria (current carbidopa/levodopa therapy, trial of entacapone or opicapone, and neurologist prescribing/consultation) are not met.

Background

Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunct to levodopa/carbidopa for treating the signs and symptoms of idiopathic Parkinson's disease. It has demonstrated efficacy for motor fluctuations but carries a Boxed Warning for potentially fatal acute fulminant liver failure, and use should be reserved and carefully monitored. Prior authorization is required when used for the FDA‑approved indication, with approvals typically granted for 1 year when all authorization criteria are met.

Definitions

Tolcapone (Tasmar) — definition and boxed warning summary

Drug class and indicationTolcapone (Tasmar) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunct to levodopa/carbidopa for treatment of signs and symptoms of idiopathic Parkinson's disease.

Brand and formulationTasmar (tolcapone tablets) — Bausch Health; generic available.

Serious safety warningBoxed Warning: risk of potentially fatal, acute fulminant liver failure — use should be reserved for patients with motor fluctuations not responding to or inappropriate for other adjunctive therapies.

Use contextIntended as adjunctive therapy for patients experiencing symptom fluctuations while on levodopa/carbidopa.

Risk-based prescribing considerationBecause of hepatotoxicity risk, tolcapone should be used only when benefits outweigh risks and alternative adjuncts have been unsuccessful or are unsuitable.